Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IntercureINCR -2.95%67 Days Payable is 99.86 as of Dec. 2025, which is 23% below its 10-year median of 130.04. GuruFocus rates INCR with a GF Score™ of 67/100 and a GF Value™ of $6.18 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 925 Drug Manufacturers companies, Intercure ranks better than 66.7% on this metric.
Intercure's average Accounts Payable for the
six
months ended in Dec. 2025 was $26.28 Mil. Intercure's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $48.03 Mil.
Hence, Intercure's Days Payable for the
six
months ended in Dec. 2025 was 99.86.
The historical rank and industry rank for Intercure's Days Payable or its related term are showing as below:
INCR'
s Days Payable Range Over the Past 10 Years
Min: 112.17 Med: 130.04 Max: 149.02
Current: 121.38
During the past 13 years, Intercure's highest Days Payable was 149.02. The lowest was 112.17. And the median was 130.04.
INCR's Days Payable is ranked better than 66.7% of 925
companies
in the Drug Manufacturers industry
Industry Median: 89.7
vs INCR: 121.38
Intercure's Days Payable
declined
from Dec. 2024 (118.66) to Dec. 2025 (99.86).
It may suggest that Intercureaccelerated paying its suppliers.
The historical data trend for Intercure's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Intercure's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intercure Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Intercure's Days Payable distribution charts can be found below:
* The bar in red indicates where Intercure's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Intercure's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intercure (INCR) has a Days Payable of 99.86 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Intercure and its competitors. This is 23% below median its historical median of 130.04. Over the past decade, Intercure's Days Payable has ranged from 112.17 to 149.02. According to the industry distribution chart, Intercure ranks #308 out of 925 companies in the Drug Manufacturers industry, placing it in the top 33.3%.
Is Intercure's Days Payable too high?
Intercure's current Days Payable of 99.86 is 23% below median its 10-year median of 130.04. Over the past 10 years, this metric has ranged from a low of 112.17 to a high of 149.02. The Drug Manufacturers industry median Days Payable is 89.70. Intercure's value of 99.86 is 11.3% above this industry median. Based on the distribution chart, Intercure ranks #308 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Intercure has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intercure's Days Payable compare to CTOR and ZYBT?
According to the Drug Manufacturers industry distribution chart, Intercure ranks #308 out of 925 companies for Days Payable. This puts Intercure in the upper half of its industry. The industry median Days Payable is 89.70. Intercure's value of 99.86 is 11.3% above this benchmark. Historically, Intercure's own Days Payable has ranged from 112.17 to 149.02 over the past decade. While the company's 10-year median is 130.04 vs. the industry median of 89.70, Intercure has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.70, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intercure's current Days Payable of 99.86 is 11.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Intercure and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intercure's current Days Payable is 99.86, which is 23% below median its own 10-year median of 130.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intercure stock overvalued right now?
Based on GuruFocus' analysis, Intercure (INCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.18, compared to a current price of $5.34 — trading 13.7% below its estimated fair value. The current Days Payable is 99.86, which is 23% below median its 10-year median of 130.04 and 11.3% above the Drug Manufacturers industry median of 89.70. Intercure's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Intercure (INCR), the current Days Payable is 99.86 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intercure (INCR) Overvalued in 2026?
Based on GuruFocus' analysis, Intercure stock appears to be undervalued.
The current stock price of $5.34 is trading 13.7% below its estimated GF Value™ of $6.18.
GuruFocus considers Intercure to be Modestly Undervalued.
Key valuation signals for INCR:
Days Payable: 99.86 (23% below median its 10-year median of 130.04)
GF Value™: $6.18 vs. price of $5.34 (13.7% below fair value)
Industry Position: 11.3% above the Drug Manufacturers median (#308 of 925)
No single metric tells the full story. See the INCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
67GF Score
Get the complete analysis for INCR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INCR has been successfully added to your 
